Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes

Biomedicine and Pharmacotherapy

Volumn 70, Issue C, 2015, Pages 33-40

  Papadopoulos, Emmanuel I ^a   Yousef, George M ^b   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

BCL2 family; Caki 1 renal cancer cell line; Everolimus; MicroRNAs; Real time PCR; Sunitinib

Indexed keywords

BCL 2 LIKE 12 PROTEIN; EVEROLIMUS; MICRORNA; MICRORNA 145; MICRORNA 15A; MICRORNA 16; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; SUNITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BCL2 PROTEIN, HUMAN; BCL2L12 PROTEIN, HUMAN; INDOLE DERIVATIVE; MUSCLE PROTEIN; PYRROLE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EXPOSURE; GENE CLUSTER; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; INCUBATION TIME; MEMBRANE DAMAGE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RENAL CANCER CELL LINE; UPREGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY NEOPLASMS; METABOLISM; MULTIGENE FAMILY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; EVEROLIMUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; KIDNEY NEOPLASMS; MICRORNAS; MULTIGENE FAMILY; MUSCLE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES;

EID: 84927556555     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.12.043     Document Type: Article

References (47)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Li L., Kaelin W.G. New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 2011, 25:667-686.
3. Escudier B., Eisen T., Porta C., Patard J.J., Khoo V., Algaba F., et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(suppl. 7):vii65-vii71.
4. Fujioka T., Obara W., Committee for Establishment of the Clinical Practice Guideline for the Management of Renal Cell Carcinoma and the Japanese Urological Association Evidence-based clinical practice guideline for renal cell carcinoma: the Japanese Urological Association 2011 update. Int J Urol 2012, 19:496-503.
5. Motzer R.J., Agarwal N., Beard C., Bolger G.B., Boston B., Carducci M.A., et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009, 7:618-630.
6. Christensen J.G. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumour activities. Ann Oncol 2007, 18(suppl. 10):x3-x10.
7. Wood L. Sunitinib malate for the treatment of renal cell carcinoma. Expert Opin Pharmacother 2012, 13:1323-1336.
8. Houghton P.J. Everolimus. Clin Cancer Res 2010, 16:1368-1372.
9. Xin H., Zhang C., Herrmann A., Du Y., Figlin R., Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009, 69:2506-2513.
10. Zitzmann K., De Toni E.N., Brand S., Göke B., Meinecke J., Spöttl G., et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007, 85:54-60.
11. Call J.A., Eckhardt S.G., Camidge D.R. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 2008, 9:1002-1011.
12. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35:495-516.
13. Thomadaki H., Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006, 43:1-67.
14. Subramanian S., Steer C.J. MicroRNAs as gatekeepers of apoptosis. J Cell Physiol 2010, 223:289-298.
15. Wahid F., Shehzad A., Khan T., Kim Y.Y. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 2010, 1803:1231-1243.
16. Krek A., Grün D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., et al. Combinatorial microRNA target predictions. Nat Genet 2005, 37:495-500.
17. Fogh J., Wright W.C., Loveless J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 1977, 58:209-214.
18. Nishimura M., Ueda N., Naito S. Effects of dimethyl sulfoxide on the gene induction of cytochrome P450 isoforms, UGT-dependent glucuronosyl transferase isoforms, and ABCB1 in primary culture of human hepatocytes. Biol Pharm Bull 2003, 26:1052-1056.
19. Monga M., Sausville E.A. Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia 2002, 16:520-526.
20. Shi R., Chiang V.L. Facile means for quantifying microRNA expression by real-time PCR. Biotechniques 2005, 39:519-525.
21. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
22. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
24. Batteiger B., Newhall W.J., Jones R.B. The use of Tween 20 as a blocking agent in the immunological detection of proteins transferred to nitrocellulose membranes. J Immunol Methods 1982, 55:297-307.
25. Chaitanya G.V., Steven A.J., Babu P.P. PARP-1 cleavage fragments: signatures of cell death proteases in neurodegeneration. Cell Commun Signal 2010, 8:31.
26. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012, 19:107-120.
27. Soldani C., Lazzè M.C., Bottone M.G., Tognon G., Biggiogera M., Pellicciari C.E., et al. Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where?. Exp Cell Res 2001, 269:193-201.
28. Gobeil S., Boucher C.C., Nadeau D., Poirier G.G. Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Differ 2001, 8:588-594.
29. Pegoraro L., Palumbo A., Erikson J., Falda M., Giovanazzo B., Emanuel B.S., et al. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci U S A 1984, 81:7166-7170.
30. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997, 275:1129-1132.
31. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74:609-619.
32. Scheltema J.M., Romijn J.C., van Steenbrugge G.J., Schröder F.H., Mickisch G.H. Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells. Anticancer Res 2001, 21:3161-3166.
33. Darwiche N., Sinjab A., Abou-Lteif G., Chedid M.B., Hermine O., Dbaibo G., et al. Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/lymphoma and apoptosis in peripheral T-cell lymphomas. Int J Cancer 2011, 129:993-1004.
34. Tirado O.M., Mateo-Lozano S., Notario V. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene 2005, 24:3348-3357.
35. Scorilas A., Kyriakopoulou L., Yousef G.M., Ashworth L.K., Kwamie A., Diamandis E.P. Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved bh2 domain of the BCL2 family. Genomics 2001, 72:217-221.
36. Kontos C.K., Scorilas A. Molecular cloning of novel alternatively spliced variants of BCL2L12, a new member of the BCL2 gene family, and their expression analysis in cancer cells. Gene 2012, 505:153-166.
37. Liu Y., Han Y., Zhang H., Nie L., Jiang Z., Fa P., et al. Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS One 2012, 7:e52280.
38. Weeraratne S.D., Amani V., Teider N., Pierre-Francois J., Winter D., Kye M.J., et al. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol 2012, 123:539-552.
39. Boominathan L. The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One 2010, 5:e10615.
40. Wotschofsky Z., Liep J., Meyer H.A., Jung M., Wagner I., Disch A.C., et al. Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci 2012, 8:1363-1374.
41. Zou C., Xu Q., Mao F., Li D., Bian C., Liu L.Z., et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle 2012, 11:2137-2145.
42. Xu Q., Liu L.Z., Qian X., Chen Q., Jiang Y., Li D., et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2012, 40:761-774.
43. Gan B., Lim C., Chu G., Hua S., Ding Z., Collins M., et al. FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell 2010, 18:472-484.
44. Sachdeva M., Liu Q., Cao J., Lu Z., Mo Y.Y. Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells. Nucleic Acids Res 2012, 40:6683-6692.
45. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005, 102:13944-13949.
46. Sun C.Y., She X.M., Qin Y., Chu Z.B., Chen L., Ai L.S., et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 2013, 34:426-435.
47. Dejean E., Renalier M.H., Foisseau M., Agirre X., Joseph N., de Paiva G.R., et al. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia 2011, 25:1882-1890.